Page 423 - The ISA Handbook in Contemporary Sociology
P. 423

9781412934633-Chap-26  1/10/09  8:57 AM  Page 394





                   394               THE ISA HANDBOOK IN CONTEMPORARY SOCIOLOGY


                   products made in Singapore can be re-   ‘intellectual property’ (IP) regime and the
                   exported to the first world (Singapore  ‘bioethics code’. The strict IP regime was to
                   Biotech Guide 2007/2008: 20).           assure large biotechnology corporations that
                     Biopolis was launched as a multi-purpose  their products would not be ‘pirated’ locally,
                   complex that could house both R&D activi-  and would not face competition from locally
                   ties as well as other corporate functions.  produced ‘generic drugs’. At the same time,
                   Costing US$350 million to build, and located  the Singapore government formed the
                   beside the National University of Singapore  Bioethics  Advisory Committee to draft a
                   Science Park, it is hoped that the complex  comprehensive set of guidelines and to make
                   will eventually accommodate 2,000 biotech-  recommendations for changes to the law
                   nology research scientists.  The Singapore  (where necessary) on various aspects such as
                   government – fully aware that the biomedical  stem cell, human tissue, and genetic research
                   sciences sector requires specialized aca-  (Singapore Bioethics  Advisory Committee
                   demic personnel (often with the minimum   Official Homepage). In addition to the high
                   of doctoral degrees in bioengineering or   quality infrastructure and the (growing) high
                   a related science) particularly for R&D   level of human resources, the IP regime and
                   activities – has also been investing heavily in  overt bioethics code would serve to enhance
                   upgrading human resources. For example,  Singapore’s competitive advantage as a loca-
                   between 2001 and 2004, 276 postgraduate  tion where large pharmaceutical corporations
                   scholars were awarded overseas and local  could operate securely.
                   government scholarships to pursue doctoral  Between 2003 and 2005, many large phar-
                   programmes in various aspects of biomedical  maceutical corporations made substantial
                   sciences, including pharmaceutical R&D  investments in Singapore. In 2003 alone,
                   (A*Star, 2005: 8). According to the director  Singapore attracted over US$500m in bio-
                           5
                   of A*Star, which is a statutory board tasked  medical – including biotechnology and
                   with promoting the biomedical initiative,  pharmaceutical FDI – related fixed asset for-
                   each scholarship recipient is expected to cost  eign investments (Beh, 2004: 36); in 2004, it
                   the government  about US$0.6m (FDI      rose to US$700m (Singapore Investment
                   Magazine, 2003: 7). Although the state has  News, December 2004 Special Supplement: 9).
                   created many opportunities for young    These recent investments included the estab-
                   Singaporeans to train to become biotechnol-  lishment of new production facilities by
                   ogy or health sciences experts, it has also  several large global pharmaceutical firms
                   gone ahead with a very liberal immigration  (see Table 26.1).
                   policy for experts (as well as postgraduate  At the same time, several other corpora-
                   students) in the pharmaceutical field, despite  tions have established fairly large biotech-
                   the expression of concern about this policy  nology or pharmaceutical research and
                   by the local population. After all, large phar-
                                                           Table 26.1  Cases of biotechnology foreign
                   maceutical corporations would be concerned
                                                           direct investment in Singapore (selected)
                   only about hiring qualified specialists regard-
                                                           Company              Investment
                   less of their nationality.
                                                           Schering-Plough Ltd 1  US$230m
                     While the state’s investments in infrastruc-    2
                                                           GlaxoSmithKline      US$100m
                   ture and human resources have been frequently  Novartis AG 3  US$200m
                   trumpeted by the Singapore government   Pfizer 4             US$375m
                   around the world as a strategy to attract   Sources:
                   pharmaceutical FDI into Singapore, there  1 Singapore Investment News, February 2004, p. 3.
                                                           2 Singapore Investment News, July 2004, p. 4.
                   were two other important policy instruments,
                                                           3 Singapore Investment News, September 2004, p. 4.
                   which were less publicized to the general  4 Singapore Investment News, October 2004, p. 6–9.
                   public.  These instruments, drawn up    Source: Singapore Economic Development Board,
                   with foreign investors in mind, were the  http://www.sedb.com.sg/
   418   419   420   421   422   423   424   425   426   427   428